Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryu Watanabe

Showing results (41-50 of 158) with videos related to

Pageof 16
Sort By:
Modern Rheumatology|March 6, 2014
Ulcerative colitis is not a rare complication of Takayasu arteritisRyu Watanabe, Tomonori Ishii, Kyohei Nakamura, et al.
American Journal of Ophthalmology Case Reports|April 11, 2020
Concomitant herpes simplex keratitis and autoimmune-associated ulcerative keratitis in rheumatoid arthritis patientsMasaaki Yoshida, Takehiro Hariya, Shunji Yokokura, et al.
Frontiers in Medicine|November 10, 2022
Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problemsRyu Watanabe, Tadashi Okano, Takaho Gon, et al.
Modern Rheumatology|July 8, 2025
Concordance between treatment guideline and daily practice in the management of eosinophilic granulomatosis with polyangiitis: A cross-sectional web-questionnaire surveyRyu Watanabe, Takao Fujii, Yoshia Miyawaki, et al.
Clinical Immunology (Orlando, Fla.)|February 18, 2019
Cytokines, growth factors and proteases in medium and large vessel vasculitisCornelia M Weyand, Ryu Watanabe, Hui Zhang, et al.
Circulation|December 20, 2017
Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel VasculitisHui Zhang, Ryu Watanabe, Gerald J Berry, et al.
Immunological Medicine|May 25, 2021
Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohortRyu Watanabe, Motomu Hashimoto, Koichi Murata, et al.
Arthritis Research & Therapy|November 13, 2020
Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: KURAMA cohortKoichi Murata, Hiromu Ito, Motomu Hashimoto, et al.
Biomolecules|November 27, 2025
The Type I Interferon Axis in Systemic Autoimmune Diseases: From Molecular Pathways to Targeted TherapyRyuhei Ishihara, Ryu Watanabe, Mayu Shiomi, et al.
The Tohoku Journal of Experimental Medicine|October 8, 2020
Multidisciplinary Approach to Prevent de novo Hepatitis B in Patients with Rheumatoid ArthritisRyu Watanabe, Takehiko Igarashi, Taro Takahashi, et al.
Pageof 16

Showing results (41-50 of 158) with videos related to

Sort By:
Pageof 16
Modern Rheumatology|March 6, 2014
Ulcerative colitis is not a rare complication of Takayasu arteritisRyu Watanabe, Tomonori Ishii, Kyohei Nakamura, et al.
American Journal of Ophthalmology Case Reports|April 11, 2020
Concomitant herpes simplex keratitis and autoimmune-associated ulcerative keratitis in rheumatoid arthritis patientsMasaaki Yoshida, Takehiro Hariya, Shunji Yokokura, et al.
Frontiers in Medicine|November 10, 2022
Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problemsRyu Watanabe, Tadashi Okano, Takaho Gon, et al.
Modern Rheumatology|July 8, 2025
Concordance between treatment guideline and daily practice in the management of eosinophilic granulomatosis with polyangiitis: A cross-sectional web-questionnaire surveyRyu Watanabe, Takao Fujii, Yoshia Miyawaki, et al.
Clinical Immunology (Orlando, Fla.)|February 18, 2019
Cytokines, growth factors and proteases in medium and large vessel vasculitisCornelia M Weyand, Ryu Watanabe, Hui Zhang, et al.
Circulation|December 20, 2017
Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel VasculitisHui Zhang, Ryu Watanabe, Gerald J Berry, et al.
Immunological Medicine|May 25, 2021
Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohortRyu Watanabe, Motomu Hashimoto, Koichi Murata, et al.
Arthritis Research & Therapy|November 13, 2020
Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: KURAMA cohortKoichi Murata, Hiromu Ito, Motomu Hashimoto, et al.
Biomolecules|November 27, 2025
The Type I Interferon Axis in Systemic Autoimmune Diseases: From Molecular Pathways to Targeted TherapyRyuhei Ishihara, Ryu Watanabe, Mayu Shiomi, et al.
The Tohoku Journal of Experimental Medicine|October 8, 2020
Multidisciplinary Approach to Prevent de novo Hepatitis B in Patients with Rheumatoid ArthritisRyu Watanabe, Takehiko Igarashi, Taro Takahashi, et al.
Pageof 16